PrimeRFP SCOUT · Federal Contract Recompete Brief

36C24622F0094Jynarque tablets 60mg 30mg — Otsuka America Pharmaceutical, Inc

The prior award was single-bid — competitive dynamics may favor a challenge. PoP ended May 27, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

246-Network Contracting Office 6 (36C246)

Awarding office

Otsuka America Pharmaceutical, Inc

Recipient

May 27, 2022

PoP end

$136K

Obligated

$136K

Potential

325412

NAICS

6505

PSC

1 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Otsuka America Pharmaceutical, Inc — $90

Contract facts

Federal

Contract number36C24622F0094

Also listed as36C246-22-F-0094

Also listed as36F79720D0099-36C24622F0094

Agency246-Network Contracting Office 6 (36C246)

Awarding office246-Network Contracting Office 6 (36C246)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentOtsuka America Pharmaceutical, Inc

CAGE0ZHV7

UEIQKABLBMA8FT9

NAICS325412

No full NAICS 325412 intel page yet. Browse NAICS intelligence

PSC6505

Parent IDIQ / IDV36F79720D0099

Place of performancePITTSBURGH PA

Pricing typeFirm Fixed Price

Extent competedFull And Open Competition

PoP startDec 30, 2021

PoP end (current)May 27, 2022

Obligated$136K

Current value$136K

Potential value$136K

JYNARQUE TABLETS 60MG/30MG is a federal award for 246-Network Contracting Office 6 (36C246) held by Otsuka America Pharmaceutical, Inc. Estimated value $136K ($136K obligated). Current period of performance ends May 27, 2022. Last award drew 1 bidder. Place of performance: PITTSBURGH PA.

Recompete timing

Public

● Past PoP end (1547 days ago)

Current PoP ended May 27, 2022 (1547 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C24622F0094?

36C24622F0094 (Jynarque tablets 60mg 30mg) is a 246-Network Contracting Office 6 (36C246) award with a potential value of $136K, currently held by Otsuka America Pharmaceutical, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C246-22-F-0094?

36C246-22-F-0094 is the dashed form of PIID 36C24622F0094 (Jynarque tablets 60mg 30mg), held by Otsuka America Pharmaceutical, Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C24622F0094?

246-Network Contracting Office 6 (36C246) awarded 36C24622F0094 to Otsuka America Pharmaceutical, Inc (potential $136K).

Who is the incumbent on 36C24622F0094?

Otsuka America Pharmaceutical, Inc is the incumbent. The current period of performance ends May 27, 2022.

When does Otsuka America Pharmaceutical, Inc’s 36C24622F0094 come up for recompete?

SCOUT tracks a period-of-performance end of May 27, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of May 27, 2022 · refreshed monthly